Meat And Bone Meal,Meat And Bone Meal For Animal Feed,Protein Powder Meat And Bone Meal fish meal,corn gluten meal ,meat and bone meal Co., Ltd. , http://www.nsmeal.com
Vandetanib Basic information
Synonyms:Â Â Â Â VANDETANIB;4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-;Vandetanib for research;4-(4-Bromo-2-fluoroanilino)-6-methoxy- 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline;N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine;Zactima;ZD 6474;7-((4-aminocyclohexyl)methoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine
CAS:443913-73-3
MF:C22H24BrFN4O2
MW:475.35Â Â Â Â
Product Categories:Aromatics Compounds;Aromatics;Heterocycles;Inhibitors;Intermediates &Â Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;ZD6474
Mol File:443913-73-3.mol
Appearance:Yellow Solid
MP:240-2430C
density:1.406
storage temp.:-20C Freezer
Vandetanib Application
â–ª Anticancer drugsÂ
Vandetanib is a kind of small molecule multi-targeted tyrosine kinase inhibitor studied and developed by the British AstraZeneca Company. In April 2011, it was approved the US FDA for entering into market under the trade name Zactima. The drug, as a tablet, can be applied to the treatment of advanced medullary thyroid cancer of adult patients.Â
Vandetanib is a multi-targeted tyrosine kinase inhibitor, and belongs to the Anilinoquinazoline compounds, called "second generation Iressa". It not only acts on the tumor cells, EGFR, VEGFR and RET tyrosine kinases, but can also inhibit other kind of tyrosine kinases and serine / threonine kinases. Vandetanib is the first approved drugs approved for treatment of medullary thyroid carcinoma. It is suitable for treating unresectable, locally advanced or metastatic-symptoms or progressive medullary thyroid carcinoma. A randomized, placebo-controlled clinical trial results have showed that vandetanib can significantly delay the progression time of locally advanced or metastatic medullary thyroid cancer. The recommended daily dose is 300 mg (oral), when the patient exhibits tolerance to drugs or being not able to tolerate the toxicity, they should stop treatment immediately. Those most common adverse reactions of this medicine include diarrhea, rash, acne, nausea, hypertension, headache, fatigue, loss of appetite and abdominal pain. The adverse reactions is dose-related; at <300 mg/d, the patient has a well tolerance with the maximum tolerated dose (MTD) being 300mg. There are many kinds disease types contained in the II phase clinical study. The NSCLC clinical trials of vandetanib are currently under way for our country.
▪  Treatment of advanced (non-small cell lung cancer) NSCLC
Â
Â
Â
▪  Preparation method   Â
Use 4-hydroxy-3-methoxy-benzoic acid ethyl ester as a starting material, go through substitution, reduction, nitrification, reduction, cyclization aromatization to give 4-chloro-6-methoxy--7- (N- methyl piperidin-4-ylmethoxy) quinazoline (A), A was then reacted with 4-bromo-2-aniline to obtain the targeted compound vandetanib.
Real figure of Vandetanib :
Vandetanib  packing :
Â
The main business is research and development, production, sales for Steroid, Active ingredient and Pharmaceutical .
  Â
Vandetanib  manufacturer production pictures:
The list of cortical hormone drugs is as follows:
Name
standard
CAS
Prednisolon Acetate
Usp32 /ep6
52-21-1
Prednisolon Base
Bp2010/Usp32/Ep7
50-24-8
Prednison
Usp32
1953/3/2
Prednison Acetate
Cp2005
125-10-0
Betamethasone Base
Ep6
378-44-9
Betamethaasone
Usp32
5593-20-4
Dipropionate
Â
Â
Budesonide
Ep5
51333-22-3
Clobetasol Propionate
Usp34
25122-46-7
Cortisone Acetate
enterprise standard
1950/4/4
Â
Â
Â
Dexamethasone Sodium Phosphate
EP6
2392-39-4
Â
Â
Â
Fluocinolone Acetonide
Usp32
67-73-2
Fluocinonide
Usp32/CP
356-12-7
Hydrocortisone
Ep7
50-23-7
Desonide
enterprise standard
638-94-8
Hydrocortisone Acetate
Ep7
1950/3/3
Dexamethasone Acetate
EP6
1177-87-3
Triamcinol0ne acetonide acetate
enterprise standard
3870/7/3
Triamcinol0n Acetonide
BP/USP/EP
76-25-5
Triamcinol0ne Base
BP/USP/EP
124-94-7
Halcinonide
Cp2005
3093-35-4
16α-Hydroxy-Prednisolone
enterprise standard
13951-70-7
Reason to choose usÂ
.Guarantee the quality of products ,our Pharmaceutical Intermediate purity≥99% .
.Variety diversification &Â Adequate stock make sure we could meet your require
.Professional service and rich experience ,we also could give you some advise aboutÂ
please feel free to contact us if you have any question.
Payment Term:T/T  , Moneygram , Western Union.
Delivery
1. Sent out in 24hours once payment comfirm.
2. Professional agent make sure our ship fastly and safety
3.Offer your tracking number to you once we get it ,in order to facilitate you track the express
Â
Vandetanib Basic information
Synonyms:Â Â Â Â VANDETANIB;4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-;Vandetanib for research;4-(4-Bromo-2-fluoroanilino)-6-methoxy- 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline;N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine;Zactima;ZD 6474;7-((4-aminocyclohexyl)methoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine
CAS:443913-73-3
MF:C22H24BrFN4O2
MW:475.35Â Â Â Â
Product Categories:Aromatics Compounds;Aromatics;Heterocycles;Inhibitors;Intermediates &Â Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;ZD6474
Mol File:443913-73-3.mol
Appearance:Yellow Solid
MP:240-2430C
density:1.406
storage temp.:-20C Freezer
Vandetanib Application
â–ª Anticancer drugsÂ
Vandetanib is a kind of small molecule multi-targeted tyrosine kinase inhibitor studied and developed by the British AstraZeneca Company. In April 2011, it was approved the US FDA for entering into market under the trade name Zactima. The drug, as a tablet, can be applied to the treatment of advanced medullary thyroid cancer of adult patients.Â
Vandetanib is a multi-targeted tyrosine kinase inhibitor, and belongs to the Anilinoquinazoline compounds, called "second generation Iressa". It not only acts on the tumor cells, EGFR, VEGFR and RET tyrosine kinases, but can also inhibit other kind of tyrosine kinases and serine / threonine kinases. Vandetanib is the first approved drugs approved for treatment of medullary thyroid carcinoma. It is suitable for treating unresectable, locally advanced or metastatic-symptoms or progressive medullary thyroid carcinoma. A randomized, placebo-controlled clinical trial results have showed that vandetanib can significantly delay the progression time of locally advanced or metastatic medullary thyroid cancer. The recommended daily dose is 300 mg (oral), when the patient exhibits tolerance to drugs or being not able to tolerate the toxicity, they should stop treatment immediately. Those most common adverse reactions of this medicine include diarrhea, rash, acne, nausea, hypertension, headache, fatigue, loss of appetite and abdominal pain. The adverse reactions is dose-related; at <300 mg/d, the patient has a well tolerance with the maximum tolerated dose (MTD) being 300mg. There are many kinds disease types contained in the II phase clinical study. The NSCLC clinical trials of vandetanib are currently under way for our country.
▪  Treatment of advanced (non-small cell lung cancer) NSCLC
Â
Â
Â
▪  Preparation method   Â
Use 4-hydroxy-3-methoxy-benzoic acid ethyl ester as a starting material, go through substitution, reduction, nitrification, reduction, cyclization aromatization to give 4-chloro-6-methoxy--7- (N- methyl piperidin-4-ylmethoxy) quinazoline (A), A was then reacted with 4-bromo-2-aniline to obtain the targeted compound vandetanib.
Real figure of Vandetanib :
Vandetanib  packing :
Â
The main business is research and development, production, sales for Steroid, Active ingredient and Pharmaceutical .
  Â
Vandetanib  manufacturer production pictures:
The list of cortical hormone drugs is as follows:
Name
standard
CAS
Prednisolon Acetate
Usp32 /ep6
52-21-1
Prednisolon Base
Bp2010/Usp32/Ep7
50-24-8
Prednison
Usp32
1953/3/2
Prednison Acetate
Cp2005
125-10-0
Betamethasone Base
Ep6
378-44-9
Betamethaasone
Usp32
5593-20-4
Dipropionate
Â
Â
Budesonide
Ep5
51333-22-3
Clobetasol Propionate
Usp34
25122-46-7
Cortisone Acetate
enterprise standard
1950/4/4
Â
Â
Â
Dexamethasone Sodium Phosphate
EP6
2392-39-4
Â
Â
Â
Fluocinolone Acetonide
Usp32
67-73-2
Fluocinonide
Usp32/CP
356-12-7
Hydrocortisone
Ep7
50-23-7
Desonide
enterprise standard
638-94-8
Hydrocortisone Acetate
Ep7
1950/3/3
Dexamethasone Acetate
EP6
1177-87-3
Triamcinol0ne acetonide acetate
enterprise standard
3870/7/3
Triamcinol0n Acetonide
BP/USP/EP
76-25-5
Triamcinol0ne Base
BP/USP/EP
124-94-7
Halcinonide
Cp2005
3093-35-4
16α-Hydroxy-Prednisolone
enterprise standard
13951-70-7
Reason to choose usÂ
.Guarantee the quality of products ,our Pharmaceutical Intermediate purity≥99% .
.Variety diversification &Â Adequate stock make sure we could meet your require
.Professional service and rich experience ,we also could give you some advise aboutÂ
please feel free to contact us if you have any question.
Payment Term:T/T  , Moneygram , Western Union.
Delivery
1. Sent out in 24hours once payment comfirm.
2. Professional agent make sure our ship fastly and safety
3.Offer your tracking number to you once we get it ,in order to facilitate you track the express
Â
Excellent Quality and Reasonable Price Vandetanib Powder as Anticancer Drugs CAS: 443913-73-3
Mf: C22h24brfn4o2
MW: 475.35
CAS: 443913-73-3
Trademark: DMK
Transport Package: Aluminum Foil Bag/Carton
Specification: API
Origin: China
HS Code: 29061310
Mf: C22h24brfn4o2
MW: 475.35
CAS: 443913-73-3
Trademark: DMK
Transport Package: Aluminum Foil Bag/Carton
Specification: API
Origin: China
HS Code: 29061310
Wuhan Deme chem Biotechnology Co., Ltd is a new and high-tech enterprise.Â
Wuhan Deme chem Biotechnology Co., Ltd is a new and high-tech enterprise.Â